|
rs121434568
|
|
Non-Small Cell Lung Carcinoma
|
|
0.800 |
GeneticVariation
|
BEFREE |
Further on, we performed a retrospective evaluation of seven patients with advanced EGFR-mutated (exon 19 deletions and L858R) NSCLC that were given erlotinib at 25 mg/d as their first EGFR TKI.
|
20512075 |
2010 |
|
rs121434568
|
|
Non-Small Cell Lung Carcinoma
|
|
0.800 |
GeneticVariation
|
BEFREE |
Clinical features of epidermal growth factor receptor (EGFR) mutations, L858R, deletions in exon 19, T790M, and insertions in exon 20, in non-small cell lung cancer (NSCLC) are well known.
|
21531810 |
2011 |
|
rs121434568
|
|
Non-Small Cell Lung Carcinoma
|
|
0.800 |
GeneticVariation
|
BEFREE |
In this double-blind, phase 3 trial, we randomly assigned 556 patients with previously untreated, EGFR mutation-positive (exon 19 deletion or L858R) advanced NSCLC in a 1:1 ratio to receive either osimertinib (at a dose of 80 mg once daily) or a standard EGFR-TKI (gefitinib at a dose of 250 mg once daily or erlotinib at a dose of 150 mg once daily).
|
29151359 |
2018 |
|
rs121434568
|
|
Non-Small Cell Lung Carcinoma
|
|
0.800 |
GeneticVariation
|
BEFREE |
Two main categories of epidermal growth factor receptor (EGFR) mutations in non-small-cell lung cancer (NSCLC) patients are deletions in exon 19 and L858R in exon 21.
|
31327643 |
2019 |
|
rs121434568
|
|
Non-Small Cell Lung Carcinoma
|
|
0.800 |
GeneticVariation
|
BEFREE |
We retrospectively analyzed a cohort of 100 patients with stage IIIB/IV NSCLC screened for two major EGFR mutations (exon 19 deletions and L858R mutation).
|
19777258 |
2010 |
|
rs121434568
|
|
Non-Small Cell Lung Carcinoma
|
|
0.800 |
GeneticVariation
|
BEFREE |
The EGFR exon 19 deletion mutation and the L858R mutation in exon 21 comprise approximately 90% of the somatic mutations in NSCLC patients that respond to EGFR TKI.
|
24913109 |
2014 |
|
rs121434568
|
|
Non-Small Cell Lung Carcinoma
|
|
0.800 |
GeneticVariation
|
BEFREE |
In the entire assessable population of 4465 EGFR-mutant NSCLC patients, significant interactions with PFS were found for gender (males vs. females; pooled ratio of the PFS-HRs = 1.2; 95% CI 1.12-1.56), smoking history (smokers vs. non-smokers; pooled ratio of the PFS-HRs = 1.26; 95% CI 1.05-1.51), and type of EGFR mutation (patients with exon 21 L858R mutation vs. exon 19 deletion; pooled ratio of the PFS-HRs = 1.39; 95% CI 1.18-1.63).
|
31466227 |
2019 |
|
rs121434568
|
|
Non-Small Cell Lung Carcinoma
|
|
0.800 |
GeneticVariation
|
BEFREE |
Pretreatment EGFR T790M mutation is more likely to coexist with L858R mutation than with exon 19 deletions in NSCLC.
|
26973206 |
2016 |
|
rs121434568
|
|
Non-Small Cell Lung Carcinoma
|
|
0.800 |
GeneticVariation
|
BEFREE |
We report three cases that were definitively diagnosed as LM from NSCLC with a mutation of epidermal growth factor receptor (<i>EGFR</i>) L858R.
|
31571928 |
2019 |
|
rs121434568
|
|
Non-Small Cell Lung Carcinoma
|
|
0.800 |
GeneticVariation
|
BEFREE |
Patients with exon 19 deletion were associated with longer progression-free survival compared to those with L858R mutation after first-line EGFR-TKIs for advanced non-small cell lung cancer: a meta-analysis.
|
25222496 |
2014 |
|
rs121434568
|
|
Non-Small Cell Lung Carcinoma
|
|
0.800 |
GeneticVariation
|
BEFREE |
Patients with NSCLCs harboring EGFR exon 19 deletions or the exon 21 L858R mutation were found to have a higher chance of response to platinum-paclitaxel (OR 9.67 [95 % CI 1.03-90.41], p = 0.047).
|
24793378 |
2014 |
|
rs121434568
|
|
Non-Small Cell Lung Carcinoma
|
|
0.800 |
GeneticVariation
|
BEFREE |
Although most EGFR mutations detected are short deletions in exon 19 or the L858R point mutation in exon 21, more than 75 different EGFR kinase domain residues have been reported to be altered in NSCLC patients.
|
17877814 |
2007 |
|
rs121434568
|
|
Non-Small Cell Lung Carcinoma
|
|
0.800 |
GeneticVariation
|
BEFREE |
We retrospectively evaluated the clinical effects of second-line platinum combination chemotherapy after first-line gefitinib treatment in NSCLC patients harboring sensitive EGFR mutations (exon 19 deletion or exon 21 L858R mutation) at five institutions.
|
25990507 |
2015 |
|
rs121434568
|
|
Non-Small Cell Lung Carcinoma
|
|
0.800 |
GeneticVariation
|
BEFREE |
In this study, we performed multiple analyses of GPCR expression in a gefitinib-resistant non-small cell lung cancer (NSCLC) cell line, H1975, which harbors an L858R/T790M mutation.
|
23144692 |
2012 |
|
rs121434568
|
|
Non-Small Cell Lung Carcinoma
|
|
0.800 |
GeneticVariation
|
BEFREE |
The antiproliferative activity of a dual PI3K/mTOR inhibitor BEZ235 was examined by the WST-1 assay and the soft agar colony-formation assay in 2 normal cell lines and 12 NSCLC cell lines: 6 expressing wild-type EGFR and 6 expressing EGFR with activating mutations, including exon 19 deletions, and L858R and T790 M point mutations.
|
31262325 |
2019 |
|
rs121434568
|
|
Non-Small Cell Lung Carcinoma
|
|
0.800 |
GeneticVariation
|
BEFREE |
Epidermal growth factor receptor 19Del and L858R exhibited distinct imaging phenotypes, which may help to guide the selection of more accurate and personalized treatment programs for patients with NSCLC.
|
31376283 |
2019 |
|
rs121434568
|
|
Non-Small Cell Lung Carcinoma
|
|
0.800 |
GeneticVariation
|
BEFREE |
Exon 19 deletions and L858R point mutation are the most commonly encountered active epidermal growth factor receptor (EGFR) mutations in non-small cell lung cancer (NSCLC), and they predict greater efficacy of gefitinib therapy.
|
25173459 |
2014 |
|
rs121434568
|
|
Non-Small Cell Lung Carcinoma
|
|
0.800 |
GeneticVariation
|
BEFREE |
Treatment of non-small-cell lung cancers (NSCLCs) harboring primary EGFR oncogenic mutations such as L858R and exon 19 deletion delE746_A750 (Del-19) using gefitinib/erlotinib ultimately fails due to the emergence of T790M mutation.
|
29568384 |
2018 |
|
rs121434568
|
|
Non-Small Cell Lung Carcinoma
|
|
0.800 |
GeneticVariation
|
BEFREE |
We enrolled patients aged 18-75 years with completely resected (R0), stage II-IIIA (N1-N2), EGFR-mutant (exon 19 deletion or exon 21 Leu858Arg) NSCLC.
|
29174310 |
2018 |
|
rs121434568
|
|
Non-Small Cell Lung Carcinoma
|
|
0.800 |
GeneticVariation
|
BEFREE |
Importantly, the TKI resistance that emerges even in cigarette smoke-exposed L858R EGFR-expressing NSCLC cells could be eliminated with Src inhibition.
|
23686837 |
2013 |
|
rs121434568
|
|
Non-Small Cell Lung Carcinoma
|
|
0.800 |
GeneticVariation
|
BEFREE |
Previously, we detected circulating tumor DNA that contained two EGFR mutations (p.L858R and exon19 del) in plasma of patients with late-stage non-small-cell lung carcinoma (NSCLC) using the electric field-induced release and measurement (EFIRM) platform.
|
30309763 |
2018 |
|
rs121434568
|
|
Non-Small Cell Lung Carcinoma
|
|
0.800 |
GeneticVariation
|
BEFREE |
The non-small cell lung cancer (NSCLC)-associated EGFR mutants, L858R and G719S, are constitutively active and oncogenic.
|
22349823 |
2013 |
|
rs121434568
|
|
Non-Small Cell Lung Carcinoma
|
|
0.800 |
GeneticVariation
|
BEFREE |
On September 27, 2018, the United States Food and Drug Administration (FDA) approved dacomitinib for the first-line treatment of patients with metastatic non-small cell lung cancer (NSCLC) with EGFR exon 19 deletion or exon 21 L858R substitution mutations.
|
31050691 |
2019 |
|
rs121434568
|
|
Non-Small Cell Lung Carcinoma
|
|
0.800 |
GeneticVariation
|
BEFREE |
Moreover, the treatment for advanced EGFR-positive NSCLC might be different between 19 Del and 21 L858R.
|
26933807 |
2016 |
|
rs121434568
|
|
Non-Small Cell Lung Carcinoma
|
|
0.800 |
GeneticVariation
|
BEFREE |
Most advanced non-small-cell lung cancers (NSCLCs) with activating epidermal growth factor receptor (EGFR) mutations (exon 19 deletions or L858R) initially respond to the EGFR tyrosine kinase inhibitors (TKIs) gefitinib and erlotinib.
|
19632948 |
2009 |